Yoshihiko Tomofuji, Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Metagenome | 3 | 2025 | 464 | 1.270 |
Why?
|
| Blood Group Antigens | 1 | 2023 | 183 | 0.790 |
Why?
|
| X Chromosome Inactivation | 1 | 2024 | 229 | 0.790 |
Why?
|
| Streptococcus intermedius | 1 | 2021 | 4 | 0.780 |
Why?
|
| Streptococcus anginosus | 1 | 2021 | 25 | 0.770 |
Why?
|
| Lupus Erythematosus, Systemic | 4 | 2023 | 2160 | 0.750 |
Why?
|
| Mi-2 Nucleosome Remodeling and Deacetylase Complex | 1 | 2020 | 116 | 0.660 |
Why?
|
| Lymphohistiocytosis, Hemophagocytic | 2 | 2020 | 272 | 0.650 |
Why?
|
| Bacteriophages | 1 | 2021 | 382 | 0.600 |
Why?
|
| Genes, Bacterial | 1 | 2021 | 1076 | 0.580 |
Why?
|
| Autoantigens | 3 | 2020 | 890 | 0.570 |
Why?
|
| Single-Cell Analysis | 3 | 2024 | 2538 | 0.540 |
Why?
|
| Genome, Human | 2 | 2025 | 4441 | 0.440 |
Why?
|
| Autoimmune Diseases | 2 | 2024 | 2255 | 0.430 |
Why?
|
| Antirheumatic Agents | 1 | 2020 | 1379 | 0.340 |
Why?
|
| Metagenomics | 2 | 2025 | 473 | 0.330 |
Why?
|
| Leukocytes, Mononuclear | 2 | 2024 | 1854 | 0.280 |
Why?
|
| Genes, X-Linked | 1 | 2024 | 129 | 0.220 |
Why?
|
| Thymus Gland | 2 | 2020 | 1264 | 0.210 |
Why?
|
| Proto-Oncogene Protein c-ets-1 | 1 | 2022 | 66 | 0.200 |
Why?
|
| Gene Expression Regulation | 1 | 2020 | 11923 | 0.200 |
Why?
|
| Fibroblasts | 2 | 2022 | 4167 | 0.180 |
Why?
|
| Genome-Wide Association Study | 4 | 2024 | 12790 | 0.180 |
Why?
|
| Hemodiafiltration | 1 | 2020 | 19 | 0.180 |
Why?
|
| Feces | 2 | 2025 | 1508 | 0.170 |
Why?
|
| Sequence Analysis, RNA | 2 | 2024 | 2040 | 0.170 |
Why?
|
| Alternative Splicing | 1 | 2024 | 1103 | 0.160 |
Why?
|
| Organ Specificity | 1 | 2024 | 1966 | 0.160 |
Why?
|
| Lupus Nephritis | 1 | 2023 | 324 | 0.160 |
Why?
|
| Myeloid Cells | 1 | 2024 | 837 | 0.160 |
Why?
|
| Plasma Exchange | 1 | 2020 | 160 | 0.160 |
Why?
|
| Interferon Type I | 1 | 2023 | 568 | 0.160 |
Why?
|
| Atrioventricular Block | 1 | 2020 | 141 | 0.150 |
Why?
|
| Japan | 1 | 2021 | 1418 | 0.140 |
Why?
|
| Metabolic Networks and Pathways | 1 | 2021 | 800 | 0.140 |
Why?
|
| Metabolome | 1 | 2023 | 1008 | 0.130 |
Why?
|
| Lymphocytes | 1 | 2024 | 2605 | 0.130 |
Why?
|
| Quantitative Trait Loci | 1 | 2024 | 2131 | 0.130 |
Why?
|
| DNA Helicases | 1 | 2020 | 854 | 0.120 |
Why?
|
| Homeodomain Proteins | 1 | 2023 | 2429 | 0.110 |
Why?
|
| Drug Resistance | 1 | 2020 | 1592 | 0.110 |
Why?
|
| Biological Products | 1 | 2023 | 948 | 0.110 |
Why?
|
| Glucocorticoids | 2 | 2020 | 2163 | 0.110 |
Why?
|
| Repressor Proteins | 1 | 2023 | 2979 | 0.100 |
Why?
|
| HEK293 Cells | 1 | 2020 | 4280 | 0.090 |
Why?
|
| Immune Tolerance | 2 | 2020 | 2322 | 0.090 |
Why?
|
| Humans | 14 | 2025 | 767040 | 0.080 |
Why?
|
| Genotype | 1 | 2023 | 13035 | 0.080 |
Why?
|
| Molecular Targeted Therapy | 1 | 2020 | 2824 | 0.080 |
Why?
|
| Mice | 4 | 2024 | 81912 | 0.070 |
Why?
|
| Arthritis, Rheumatoid | 1 | 2022 | 3778 | 0.070 |
Why?
|
| Immunosuppressive Agents | 1 | 2020 | 4210 | 0.070 |
Why?
|
| Transcription Factors | 3 | 2022 | 12158 | 0.060 |
Why?
|
| Mice, Inbred C57BL | 2 | 2020 | 22361 | 0.060 |
Why?
|
| Case-Control Studies | 1 | 2021 | 22254 | 0.060 |
Why?
|
| Graves Disease | 1 | 2024 | 239 | 0.050 |
Why?
|
| B-Cell Activating Factor | 1 | 2023 | 116 | 0.050 |
Why?
|
| Nerve Tissue Proteins | 1 | 2015 | 4401 | 0.050 |
Why?
|
| T-Lymphocytes | 1 | 2020 | 10254 | 0.050 |
Why?
|
| Animals | 4 | 2024 | 168965 | 0.050 |
Why?
|
| Female | 5 | 2025 | 396660 | 0.050 |
Why?
|
| Lymphotoxin beta Receptor | 1 | 2020 | 26 | 0.050 |
Why?
|
| Sorption Detoxification | 1 | 2020 | 1 | 0.040 |
Why?
|
| RANK Ligand | 1 | 2022 | 321 | 0.040 |
Why?
|
| Kidney Glomerulus | 1 | 2023 | 571 | 0.040 |
Why?
|
| Dipeptidyl Peptidase 4 | 1 | 2020 | 93 | 0.040 |
Why?
|
| Autoimmunity | 2 | 2020 | 1361 | 0.040 |
Why?
|
| Receptors, Platelet-Derived Growth Factor | 1 | 2020 | 178 | 0.040 |
Why?
|
| Matrix Metalloproteinases | 1 | 2022 | 391 | 0.040 |
Why?
|
| Male | 5 | 2025 | 364203 | 0.040 |
Why?
|
| DNA-Binding Proteins | 1 | 2015 | 9612 | 0.040 |
Why?
|
| Adult | 3 | 2021 | 223317 | 0.040 |
Why?
|
| Treatment Outcome | 2 | 2020 | 65295 | 0.030 |
Why?
|
| Computational Biology | 1 | 2025 | 3567 | 0.030 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2025 | 3667 | 0.020 |
Why?
|
| Skin | 1 | 2025 | 4499 | 0.020 |
Why?
|
| Immunity, Innate | 1 | 2023 | 3076 | 0.020 |
Why?
|
| Membrane Glycoproteins | 1 | 2020 | 3702 | 0.020 |
Why?
|
| Mice, Transgenic | 1 | 2020 | 9551 | 0.020 |
Why?
|
| Kidney | 1 | 2023 | 7063 | 0.020 |
Why?
|
| Middle Aged | 1 | 2021 | 223233 | 0.020 |
Why?
|
| Cytokines | 1 | 2020 | 7446 | 0.020 |
Why?
|
| Signal Transduction | 2 | 2020 | 23621 | 0.010 |
Why?
|
| Inflammation | 1 | 2024 | 10869 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 2020 | 18989 | 0.010 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2024 | 18063 | 0.010 |
Why?
|
| Anti-Bacterial Agents | 1 | 2020 | 7469 | 0.010 |
Why?
|
| Young Adult | 1 | 2020 | 59980 | 0.010 |
Why?
|